The extent of regional lymph node (LN) metastasis is the most important factor in the evaluation of resectability and prognosis of non-small cell lung cancer (NSCLC) to increase the chance of complete cure. The authors attempted to deduce a group of genes from the analysis of mRNA expression profiles of the tumor tissues of NSCLC patients with or without LN metastasis, and make a classification model for better prediction of LN metastasis. Methods: The authors analyzed mRNA expression profiles of 79 NSCLC patients with or without LN metastasis, and deduced the gene signature for the predictive model of LN metastasis in lung cancer. The authors evaluated the predictive accuracy of each of four algorithms by applying them to another set of 33 NSCLC patients. Each algorithm's accuracy was calculated by 10-fold cross-validation, and a combined model showed a level of accuracy that was higher than any one of the better three component algorithms (i.e., ANN, DT, or NB). Avadis, SAS, ArrayXPath, and R-package were the statistical analysis software packages used. Results: The authors selected 949 genes using a classical permutation t test (p Ͻ 0.01) and finally obtained a gene signature consisting of 31 genes by adjustment of multiple-hypothesis testing. The LN metastasis prediction model derived from the signature (31 genes) and their characteristic interactions provided a predictive accuracy of 84.85% when applied to a test set of 33 patients.
T he optimal treatment of lung cancer relies on accurate disease staging, which is based on tumor size, regional nodal involvement, and the presence of metastasis. In particular, the extent of regional lymph node (LN) metastasis is the most important prognostic factor for those patients with resectable lung cancer. The cure rate following surgery is considerably lower if there is any LN involvement (Ͻ50% for stage II disease and 30% for stage IIIA disease). 1 Although computed tomography (CT) has been widely used for the preoperative evaluation of tumor size and the invasion of adjacent structures, many studies have shown that CT has limitations for the staging of lung cancer because of its low reliability for LN staging. [2] [3] [4] [5] The predictability of hilar or peribronchial LN metastasis (N1 disease) is even lower than that of mediastinal LN metastasis (N2 disease). 6 Recently, positron emission tomography (PET) using 18 F-fluorodeoxyglucose has been reported to increase the diagnostic accuracy for the differentiation of benign and malignant lesions and to improve the identification of nodal metastasis. However, it has been reported that 18 F-fluorodeoxyglucose PET is significantly less specific in depicting LN metastasis, especially in geographic areas with endemic granulomatous disease. 7 Thus, to improve the cure rate, we need a more reliable tool with which to assess preoperative LN metastasis. The mechanisms by which malignant tumors leave the primary tumor site, invade the lymphatic system, and metastasize to the regional LNs are poorly understood. However, we are able to acquire information concerning which genes are differentially expressed according to such clinical parameters as LN metastasis, distant metastasis, recurrence, and survival. 8 -14 Therefore, analysis of the differentially expressed genes between LN metastatic tumors and nonmetastatic tumors might allow researchers a better understanding of the pathogenesis of LN metastasis.
Obtaining mRNA expression profiles is an appropriate method for measuring the levels of expression for all genes in cancer. Along with clinical features, it may help to determine prognostic subgroups of cancer. It has been reported that cDNA microarray analysis could classify the subgroups of lung adenocarcinomas according to gene expression profiles and help create a risk index for survival. 12 Moreover, studies have used mRNA expression profiles as an adjunct to clinical decision-making. For example, several recent reports have suggested that gene expression profiles can predict recurrence of Dukes' stage B colon cancers, 10 diagnose LN metastasis from primary head and neck squamous cell carcinoma, 15 and predict the therapeutic response to docetaxel in patients with breast cancer. 16 In this study, we attempted to deduce a group of genes from the analysis of mRNA expression profiles of the tumor tissues of NSCLC patients with or without LN metastasis, and create a classification model with the genes and an appropriate algorithm. Then, we investigated whether the model could predict the classification of regional LN metastasis involvement in another set of new NSCLC patients with reasonably high accuracy.
PATIENTS AND METHODS

Patients
Frozen tissues were collected from 302 patients among a total of 923 patients with primary NSCLC who underwent lung resection from January of 1995 to December of 2001 at the Samsung Medical Center, where the following patients were excluded: those with small cell or low-grade malignancy histology such as adenoid cystic carcinoma or atypical carcinoid, multiple pulmonary tumor nodules, preoperative neoadjuvant treatment for pathologically proven mediastinal LN metastases, chest or mediastinal invasion without LN metastasis (T3N0), or malignant pleural effusion, and patients who underwent an incomplete resection or who were without mediastinal node dissection. Frozen tissues were further selected by excluding the ones with less than 90% tumor cells in the microdissected specimen and the ones with degraded RNAs. As a result, frozen tissue specimens from 112 patients were used for the study. The clinical profiles of those patients consisting of 70 LN-negative patients and 42 LN-positive patients are shown in Table 1 . Histologic types of samples were 48 adenocarcinomas, 58 squamous cell carcinomas, and six large cell carcinomas; 46 patients showed recurrence.
Tissue Preparation and RNA Extraction
Systematic LN dissection was performed for all cases by thoracotomy after routine mediastinoscopy. All the LNs encountered were removed from the American Thoracic Society LN map areas 11, 10, 9, 8, 7, 4, 3, and 2 for the tumors of the right lung; and from areas 11, 10, 9, 8, 7, 6 , and 5 for the tumors of the left lung. 17 An average of six (range, five to eight) mediastinal stations were dissected. All the surgically removed tissues were immediately examined by experienced pathologists. One or two pieces (5 ϫ 5 mm) of tumor tissue from the periphery of the tumor mass-to avoid the necrotic region-were immediately stored at -80°C until retrieved for the study.
The medical records were reviewed retrospectively, and the available hematoxylin and eosin slides of the LNs were reviewed by board-certified pathologists. A total of 2188 LNs were dissected from all the patients (the number of LNs per patient, 21.3 Ϯ 10.6; range, 8 -54), and 152 nodes were positive for metastasis.
Three hundred two frozen tissues were microdissected and lightly stained with hematoxylin to improve visualization. After staining, the dried frozen tissues and the tumor tissue containing normal cells that could not be microdissected were excluded. One hundred sixty-three tissues were used for RNA extraction, and the tissues having degraded RNA were removed. Finally, 112 tumor tissue specimens were used for the oligonucleotide microarray experiment. Each microdissected specimen for the study contained more than 90% tumor cells.
The microdissected tumor tissues were placed in 1 ml of Trizol reagent (Life Technologies, Rockville, MD) and immediately homogenized by vortexing. The total RNA was isolated according to the Trizol reagent protocol. The quality of the total RNA was analyzed by electrophoresis using a 1% agarose gel containing 0.6 M formaldehyde and ethidium bromide. The quantity of the total RNA was analyzed using a Nanodrop spectrometer (Nanodrop Technologies, Rockland, DE).
Microarray Hybridization Analysis
Approximately 5 to 10 g of the total RNA from the tumor tissues was used for the oligonucleotide microarray analysis (Macrogen, Seoul, Korea), and the remainder was used for reverse-transcriptase polymerase chain reaction (PCR) or real-time PCR. The Macrogen Oligo Human 10K microarray had been made by spotting 50-mer oligonucleotide probes that represented 10,416 human genes, 8032 known genes, and 2076 expressed sequence tags. 18 Each of the 112 total RNAs was hybridized with a universal human reference RNA (Stratagene, La Jolla, CA), and the oligonucleotide microarray hybridizations, scanning, and normalizations were carried out as described previously. 18 
Validation of Array Data with Real-Time Quantitative PCR
To validate the results of the oligonucleotide microarray analysis, two genes and 16 randomly selected samples were analyzed using real-time quantitative (RTQ) PCR (PCR). The same 16 poly-A RNAs used in the microarray analysis were reverse-transcribed with oligo(dT) priming (Superscript II; Life Technologies). RTQ-PCR was performed with specific primers for BCL-3 and GZMA. The expression of the housekeeping gene GAPDH was used to normalize for variances in the input cDNA. A relative standard curve representing three 10-fold dilutions of cDNA from the mixed lung tissue samples (1:10:100:1000) was used for the linear regression analyses of the unknown samples. The cycling parameters used were 10 minutes at 95°C, 40 RTQ-PCR cycles of 15 seconds at 95°C and 60 seconds at 60°C for extension performed using an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) with a TaqMan Universal PCR Master Mix (Roche, Branchburg, NJ). Real-time monitoring of the PCR products was performed with the fluorescent dye FAM (Applied Biosystems). The expression levels of the specific genes were represented as their ratios against GAPDH. The PCR primer pairs (5= to 3=) used for each gene were BCL-3 (catalogue No. Hs00180403_m1; Applied Biosystems) and GZMA (catalogue No. Hs00196206_m1; Applied Biosystems). Relatively high correlation between the results of microarray results and those of RTQ-PCR allowed us to proceed with the subsequent statistical analysis (data not shown).
Array Data Analysis and Classification Modeling
The microarray hybridization images were scanned and analyzed using ImaGene version 5.5 software (BioDiscovery, El Segundo, CA), and the data were normalized by the Lowess method, in which the value of the Cy-5/Cy-3 ratio was log transformed with base 2. Hierarchical clustering was performed to check whether the gene expression profiles of tumor tissues were significantly distinguishable between the presence and the absence of a patient's LN metastasis. Then, a permutation t test followed by multiple testing adjustment with the Westfall-Young method was conducted to select differentially expressed genes or signature.
Three algorithms (i.e., artificial neural network, decision tree, and naive Bayes) showed an acceptable level (Ͼ80%) of predictive accuracy in our case. However, to develop a classification model with a higher accuracy of LN metastasis prediction, we integrated a voting scheme in the combination of those three algorithms, where a positive or negative label for LN metastasis status was assigned when two or three individual algorithms agreed.
Validation of the Classification Model
The classification model obtained from the above training set of 79 patients was tested for its predictive accuracy by applying the test to a set of 33 new patients.
RESULTS
Location and Extent of LN Metastasis In NSCLC
Among 79 patients in our training samples, 49 (62%) were staged as pN0 and 30 (38%) showed lymphatic spread; 10 patients (33%) were staged as pN1 and 20 patients (67%) as pN2 according to the 1997 TNM classification. In 33 new samples for testing the developed model, 21 patients were pN0 and 12 patients showed lymphatic spread (N1, four patients; N2, eight patients) ( Table 1 ). More than 2000 nodes (n ϭ 2349), with an average of 21 LNs (range, 8 -54) per patient, were clinicopathologically analyzed for metastatic infiltration. One hundred forty-eight LNs (6.3%) showed metastatic involvement, whereas 2201 LNs (93.7%) were free of tumor infiltration. LN involvement was present in 44% of the patients with squamous cell carcinoma and in 33% of the patients with large cell carcinoma. For patients with adenocarcinoma, the rate of LN involvement was 29%.
Distinctive Expression Profiles of Primary Tumors with LN Metastatic Involvement
We prepared mRNA expression profiles derived from primary tumors with or without LN metastatic involvement using oligonucleotide microarray and checked for the global discrepancy in gene expression between the two groups of tumors using hierarchical clustering. The results demonstrate that LN metastasis status was discriminated well, indicating the possibility of selecting a group of genes involved in LN metastasis (Figures 1 and 2) .
Selection of LN Metastasis-Discriminating Genes
To identify the differentially expressed genes between patients with and without LN metastasis, we divided the 112 patients by stratified random sampling into two groups, 79 (49 without LN metastasis and 30 with LN metastasis) and 33 as the training set and the test set, respectively. Then, we analyzed the mRNA expression profiles from the training set and carried out the statistical analysis as described previously to generate a gene signature. We found that the signature consisted of 31 genes (p Ͻ 0.05) (i.e., 27 known genes and four expressed sequence tags), and their characteristics are summarized in Table 2 .
Functional Classification of the Selected Discriminatory Genes
To obtain a brief overview of the general functional features of the LN metastasis-associated genes in NSCLC, we performed the classification and analysis of functions for the 949 genes (p Ͻ 0.01) that resulted from the t test before the multiple testing adjustment using the ArrayXPath. The results were deposited at the following website: http://biosvg.snubi. org:8080/ArrayXPath/ArrayXPath_SonDaeSoon_949.html. Specifically, 222 of 949 genes were identified in four public pathway databases (GenMAPP, PharmGKB, KEGG, and BioCarta) using ArrayXPath. 19 The results are useful for searching genes involved in cell proliferation, migration, and survival that are essential to LN metastasis in cancer cells.
Thirty-one genes as the signature for LN metastasis seem to be related to tumorigenesis and tumor suppression, which is supported by the following facts on the component genes: AATF, a recently identified human Rb-binding protein that inhibits the Rb growth suppressing function 20 ; BAT3, related to apoptosis by caspase-3-mediated proteolytic activation 21 ; and Cyb561, associated with senescence. 22 Further facts come from other genes: GPC4 binds FGF2 and modulates fibroblast growth factor signal transduction 23 ; Mcm3 expression appeared to be higher in cancer cells than in normal proliferating cells of the uterine cervix and dysplastic cells 24 ; MUC5AC is a target gene of epidermal growth factor receptor ligands in lung cancer cells, and up-regulation of this gene goes through concomitant activation of the epidermal growth factor receptor/Ras/Raf/extracellular signal-regulated kinase-signaling pathway and Sp1 binding to their promoters 25 ; SOX6 may be a potential diagnostic marker for gliomas 26 ; and TGIF2 may play an important role in the development and/or progression of some ovarian tumors through a mechanism of gene amplification. 27 
Development of the LN Metastasis Prediction Model and Its Predictive Accuracy
Next, we developed the LN metastasis prediction model using this gene signature and the modified algorithm described previously. When we tested this model for its predictive accuracy on the test set of 33 new patients, we achieved a sensitivity of 83.33% and a specificity of 85.71%, which is more accurate for the prediction of LN metastasis than obtained by any of the algorithms (Table 3) . Our LN metastasis prediction model, which has been applied successfully to patients with their clinical information undisclosed, showed another practical example of being a useful prediction model as collectively structured parameters, not by one or a few individual genes involved.
DISCUSSION
Because preoperative chemotherapy plus surgery allows an increased median survival for patients with pathologically proven ipsilateral mediastinal lymph node metastasis (pathological N2 stage IIIA), 3, 4 the neoadjuvant approach has been examined for earlier disease, such as stage IB, IIA, and IIB. However, contrary to the promising expectations, the outcomes of the previous studies were disappointing. In the phase II Bimodality Lung Oncology Team study performed by Pisters et al., although 53 of 94 (56%) patients had a major objective response after induction chemotherapy, only 81 patients (86%) had complete resection. 28 Considering that the candidates had T2N0, T1-2N1, or T3N0-1 staged NSCLC and more than 95% had R0 resection (i.e., complete resection with negative resection margins), this was too low a resection rate, and the unnecessary delay of surgery may have been attributable to unresectability. In addition, there was no remarkable survival benefit identified at 1 and 2 years after In the Bimodality Lung Oncology Team study, despite performing modern CT imaging and mediastinoscopy, clinical staging was practically inaccurate, because only 16% of patients showed an equivalent clinical and pathological stage. 28 If induction chemotherapy might be effective only for patients with regional lymph node metastasis, surgery for patients with stage I NSCLC might have been unnecessarily delayed and the chance for survival was inadvertently taken away.
Therefore, the accurate preoperative assessment of LN involvement for patients with NSCLC is crucial for treatment planning. Imaging modalities such as CT, magnetic resonance imaging, and transesophageal endosonography provide limited predictive value in differentiation between benign and malignant nodes. McLoud et al. have shown that CT gives a sensitivity of 64% and a specificity of 62% when extensive sampling of nodes with a diameter of 1 cm as the upper limit is allowed. 2 PET and endoscopic ultrasound provide sensitivities of 84% and 78% and specificities of 89% and 71%, respectively, in diagnosis of LN metastasis in NSCLC. 29 In the pretherapeutic LN staging of NSCLC, it has long been assumed that there exists a correlation between node size and metastatic infiltration. However, Prenzel et al. showed a lack of a statistically significant relationship between the size of the LNs and the likelihood of malignancy in a study of 2891 regional LNs from 256 patients. 6 Similar disappointing results were reported by Vogel et al. after investigation of 162 mediastinal LNs in 83 patients. 30 Despite these findings, CT still has been the method of choice for assessing LN metastasis in lung cancer.
In contrast, some researchers have tried to identify patients with LN metastasis by using biological methods. Analysis of serum vascular endothelial growth factor, microsatellite instability, or peanut agglutinin-binding carbohydrates in tumor suggested that these factors are related to nodal metastasis in lung cancer. [31] [32] [33] [34] However, tumor metastasis is a complex process that involves many interactions between tumor cells and the extracellular matrix so that some individual genetic changes discovered cannot be generalized and are impractical to apply to clinical situations. Extensive analysis of mRNA expression profiles or protein expression profiles on a scale and with the sensitivity unattainable by conventional techniques has been made possible by the improvement in high-throughput technologies. For lung cancer, these clinical genomic or proteomic approaches have identified subgroups of tumors that differ in terms of tumor type, histologic subclass, and patient survival, allowing prediction of regional LN metastasis with a small number of patients. 12 The result of this study showed the possibility that gene signatures from mRNA expression profiling can predict LN metastasis with high accuracy for NSCLC. However, to be used in clinical practice such as in planning of preoperative chemotherapy, biopsy specimens should be collected from the primary tumor lesion and then analyzed for gene expression. Successful application of such a technique has already been reported by Borczuk et al. 35 Although multigene signatures from mRNA expression profiling can predict LN metastasis, the extent of the metastasis, such as number of metastatic LNs or the delineation between N1 and N2, cannot be identified because the distinction between N1 and N2 is made by anatomical, not biological, criteria. Therefore, when preoperative analysis of gene expression of the biopsy specimen suggests possible LN metastasis, mediastinoscopy is imperative to discern N1 disease from N2 or N3 disease.
Even though we could select a group of genes from mRNA expression profiling, some individual genes in the group might not be useful for predicting LN metastasis as mentioned earlier because of the complexity of most types of cancer and the compound nature of gene functions. Thus, it is desirable that gene sets representing the characteristic gene expression profiles of LN metastasis are selected and their interactions interpreted as a whole in a reasonably acceptable manner. Furthermore, because our ultimate goal is prediction of LN metastasis for new patients with the model developed from the fixed data, the model's robustness is essential for the classification algorithm. For this reason, we decided to seek a modified model constructed from a series of known classification algorithms. We calculated the accuracy by 10-fold cross-validation for each algorithm and then selected and combined three independent algorithms (ANN, DT, and NB), showing a greater than 85% accuracy. We found the robustness in the resultant modified algorithm, which is good for accuracy in sound judgment.
CONCLUSIONS
In our study with the long-term goal of validating our gene set as a whole and not as individual genes for their effective prospective discrimination of LN metastasis, we selected genes by a modified algorithm that had been derived by combining the last three of the above algorithms with a voting scheme. Our selected gene sets and their modeled interactions significantly improved the predictive accuracy of LN metastasis in the training set of patients compared with the other unmodified algorithms, and showed the prediction with high accuracy in the test set of patients. For ideal validation of this classification model, we should apply this model to another set of mRNA expression profiles from a new set of patients. This would provide us with an additional chance to refine the current model to the integrated version, allowing for even more accurate prediction.
